Want to see AU:ATX full AI Analyst Report?
Top Page
Amplia Therapeutics
(Sydney:ATX)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.15
▲(7.14% Upside)
Action:Reiterated
Date:05/30/26
The score is driven primarily by weak financial performance—zero revenue in the latest year, persistent losses, and worsening cash burn—partly offset by a comparatively strong equity-backed balance sheet. Technicals are also soft with the price below key moving averages and negative MACD, while valuation is difficult to support due to negative earnings and no dividend yield data.
Positive Factors
Equity-backed balance sheet
A large equity cushion relative to assets and low leverage materially reduces short-term solvency risk and the need for immediate high-cost financing. Over a multi-month horizon this provides runway for R&D and clinical milestones, lowering dilution risk if management paces spend to milestones.
Negative Factors
No current revenue
The absence of revenue undermines operational self‑funding and prevents validation of commercial demand. Over a 2–6 month horizon this remains a durable weakness: without monetized products or external financing the company must rely on capital markets or partners, raising execution and dilution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Equity-backed balance sheet
A large equity cushion relative to assets and low leverage materially reduces short-term solvency risk and the need for immediate high-cost financing. Over a multi-month horizon this provides runway for R&D and clinical milestones, lowering dilution risk if management paces spend to milestones.
Read all positive factors
Amplia Therapeutics (ATX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$71.86M
Dividend YieldN/A
Average Volume (3M)525.22K
Price to Earnings (P/E)―
Beta (1Y)0.11
Revenue GrowthN/A
EPS Growth21.23%
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding513,312,000
10 Day Avg. Volume444,673
30 Day Avg. Volume525,217
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-12.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Amplia Therapeutics Business Overview & Revenue Model
Company Description
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor o...
How the Company Makes Money
null...
Amplia Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
30
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 3.78M | 4.45M | 1.19M | 1.98M |
| Gross Profit | -92.14K | 3.57M | 4.01M | 1.12M | 1.98M |
| EBITDA | -13.09M | -6.78M | -4.48M | -7.26M | -3.64M |
| Net Income | -7.71M | -6.57M | -4.50M | -6.24M | -3.64M |
Balance Sheet | |||||
| Total Assets | 41.44M | 22.94M | 14.85M | 18.68M | 24.48M |
| Cash, Cash Equivalents and Short-Term Investments | 27.85M | 10.86M | 3.39M | 9.26M | 14.61M |
| Total Debt | 341.11K | 13.89K | 1.59M | 2.27M | 2.10M |
| Total Liabilities | 1.97M | 1.91M | 3.43M | 2.85M | 2.64M |
| Stockholders Equity | 39.47M | 21.02M | 11.42M | 15.84M | 21.85M |
Cash Flow | |||||
| Free Cash Flow | -8.77M | -6.89M | -5.13M | -5.31M | -4.42M |
| Operating Cash Flow | -8.73M | -6.89M | -5.13M | -5.29M | -4.40M |
| Investing Cash Flow | -96.22K | -2.07K | -2.23K | -58.42K | -26.64K |
| Financing Cash Flow | 25.94M | 14.32M | -772.98K | -84.22K | 17.19M |
Amplia Therapeutics Technical Analysis
Negative
0.14
Price Trends
0.13
Positive
0.14
Negative
0.14
Negative
Market Momentum
<0.01
Negative
49.17
Neutral
38.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ATX, the sentiment is Negative. The current price of 0.14 is above the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.13, and below the 200-day MA of 0.14, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 49.17 is Neutral, neither overbought nor oversold. The STOCH value of 38.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ATX.
Amplia Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$2.12B | 68.79 | 9.20% | ― | -69.69% | -78.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$133.82M | -8.79 | -30.19% | ― | ― | 62.66% | |
45 Neutral | AU$55.48M | -10.77 | -104.56% | ― | ― | 57.89% | |
43 Neutral | AU$71.86M | -8.08 | -18.71% | ― | ― | 21.23% | |
43 Neutral | AU$99.42M | -1.87 | -265.55% | ― | -26.58% | -100.90% | |
39 Underperform | AU$5.95M | -1.56 | 56.41% | ― | ― | ― |
* Healthcare Sector Average
AU:ATX
Amplia Therapeutics
0.14
-0.19
-57.81%
AU:ENP
Tryptamine Therapeutics
0.03
<0.01
9.68%
AU:NEU
Neuren Pharmaceuticals Limited
16.78
2.17
14.85%
AU:PAR
Paradigm Biopharmaceuticals
0.17
-0.26
-60.47%
AU:ATH
Alterity Therapeutics
0.65
-0.10
-14.00%
AU:ZLD
Zelira Therapeutics
0.50
0.09
21.95%
Amplia Therapeutics Corporate Events
Amplia Therapeutics appoints Brett Carter as director amid progress in pancreatic cancer trials
Jul 6, 2026
Amplia Therapeutics Limited has filed an Initial Director’s Interest Notice announcing the appointment of Brett Anthony Carter as a director of the company, noting that he currently holds no relevant interests in Amplia’s securities. T...
Amplia strengthens board with industry deal-maker Brett Carter
Jul 5, 2026
Amplia Therapeutics has appointed biopharmaceutical executive Brett Carter as a non-executive director, strengthening its board as lead drug narmafotinib moves into later-stage development. Carter brings more than 25 years of global oncology, corp...
Amplia Therapeutics Sets August AGM Amid Progress in FAK Cancer Trials
Jun 30, 2026
Amplia Therapeutics has scheduled its Annual General Meeting for Friday 28 August 2026, covering the financial year ended 31 March 2026, with venue and detailed arrangements to be confirmed. The company has also opened nominations for the election...
Amplia Therapeutics reshapes board leadership as clinical momentum builds
Jun 29, 2026
Amplia Therapeutics has announced a planned change in board leadership as part of its renewal and succession strategy, with long-serving chairman Dr Warwick Tong stepping down from the chair role while remaining on the board as a non-executive dir...
Amplia lodges updated ASX corporate governance statement for 2026
May 29, 2026
Amplia Therapeutics has lodged its updated corporate governance statement for the year ended 31 March 2026, confirming that the document is current as of 27 May 2026 and is available on its website. The filing, accompanied by a completed Appendix ...
Amplia Therapeutics details ASX-aligned corporate governance framework
May 29, 2026
Amplia Therapeutics has formalised its governance framework in line with the ASX Corporate Governance Council’s latest principles, detailing a clear Board Charter that defines the respective roles of directors and management. The board retai...
Amplia Highlights Cancer and Fibrosis Focus in 2025-26 Report
May 29, 2026
Amplia Therapeutics has released its 2025-2026 annual report, underscoring its commitment to innovating therapies for cancer and fibrotic diseases. The report positions the company as a purpose-driven biotech player, highlighting its broader focus...
Amplia Issues New Shares Under Executive Equity Plan, Affirms Regulatory Compliance
May 12, 2026
Amplia Therapeutics has issued 240,385 fully paid ordinary shares following the exercise of Zero Exercise Price Options granted to its Chief Medical Officer under the company’s Equity Incentive Plan. The new shares rank equally with existing...
Amplia Therapeutics Adds 240,385 New Shares to ASX Listing
May 12, 2026
Amplia Therapeutics Limited has applied for quotation of 240,385 new ordinary fully paid shares on the Australian Securities Exchange. The new securities, issued on May 12, 2026, arise from the exercise or conversion of existing options or other c...
Amplia and ANZGOG launch narmafotinib ovarian cancer trial targeting high‑need patients
May 8, 2026
Amplia Therapeutics has partnered with the Australia New Zealand Gynaecological Oncology Group to run a new investigator-initiated trial of its lead FAK inhibitor narmafotinib in ovarian cancer, expanding beyond its current pancreatic cancer progr...
Amplia advances narmafotinib program with strong pancreatic cancer data and Phase 3 readiness steps
Apr 28, 2026
Amplia Therapeutics reported further clinical and operational progress for its lead FAK inhibitor narmafotinib in the March 2026 quarter, highlighted by mature data from the ACCENT trial in metastatic pancreatic cancer showing a median overall sur...
Amplia Halts New Recruitment in Pancreatic Cancer Trial After Chemo Toxicities
Apr 8, 2026
Amplia Therapeutics has paused further recruitment in its AMPLICITY clinical trial in advanced pancreatic cancer after three dose-limiting toxicities were linked to the chemotherapy regimen mFOLFIRINOX, while confirming no toxicity concerns relate...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.